Advances in biomarkers for the early diagnosis of prostate cancer / 癌症
Chinese Journal of Cancer
;
(12): 229-233, 2010.
Artículo
en Inglés
| WPRIM
| ID: wpr-292604
ABSTRACT
More and more studies have revealed that the level of serum prostate specific antigen(PSA) has little value for early diagnosis of prostate cancer (PCa). For example, negative prostate biopsies are as high as 70%-80% for patients with serum PSA ranging between 4 ng/mL and 10 ng/mL. However, the negative results cannot exclude the existence of cancer. In the studies of the early diagnosis of PCa, investigators focused on seeking biomarkers that have higher sensitivity and specificity. Recently, PSA derivatives, HPC1, PCA3, TMPRSS2 ETS, GSTP1, AMACR, GOLPH2, EPCA, sarcosine, and the combination of multiple biomarkers are widely discussed. In this article, we have reviewed their recent development and the prospective value of the combination of multiple biomarkers, which may be helpful for the early diagnosis and the prognostic monitoring of patients with PCa.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Neoplasias de la Próstata
/
Sarcosina
/
Biomarcadores de Tumor
/
Proteínas de Fusión Oncogénica
/
Antígeno Prostático Específico
/
Racemasas y Epimerasas
/
Diagnóstico Precoz
/
Diagnóstico
/
Endorribonucleasas
/
Gutatión-S-Transferasa pi
Tipo de estudio:
Estudio diagnóstico
/
Estudio de tamizaje
Límite:
Humanos
/
Masculino
Idioma:
Inglés
Revista:
Chinese Journal of Cancer
Año:
2010
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS